High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

Por Yellen, Paige, Saqcena, Mahesh, Salloum, Darin, Feng, Jiangnan, Preda, Angela, Xu, Limei, Rodrik-Outmezguine, Vanessa, Foster, David A
Publicado em 2011

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Por Chandarlapaty, Sarat, Sawai, Ayana, Scaltriti, Maurizio, Rodrik-Outmezguine, Vanessa, Grbovic-Huezo, Olivera, Serra, Violeta, Majumder, Pradip K., Baselga, Jose, Rosen, Neal
Publicado em 2011

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

Por Rodrik-Outmezguine, Vanessa S., Chandarlapaty, Sarat, Pagano, Nen C., Poulikakos, Poulikos I., Scaltriti, Maurizio, Moskatel, Elizabeth, Baselga, José, Guichard, Sylvie, Rosen, Neal
Publicado em 2011

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling

Por Will, Marie, Qin, Alice Can Ran, Toy, Weiyi, Yao, Zhan, Rodrik-Outmezguine, Vanessa, Schneider, Claudia, Huang, Xiaodong, Monian, Prashant, Jiang, Xuejun, de Stanchina, Elisa, Baselga, Jose, Liu, Ningshu, Chandarlapaty, Sarat, Rosen, Neal
Publicado em 2014

Feedback suppression of PI3Kα signaling in PTEN mutated tumors is relieved by selective inhibition of PI3Kβ

Por Schwartz, Sarit, Wongvipat, John, Trigwell, Cath B., Hancox, Urs, Carver, Brett S., Rodrik-Outmezguine, Vanessa, Will, Marie, Yellen, Paige, de Stanchina, Elisa, Baselga, José, Scher, Howard I., Barry, Simon T., Sawyers, Charles L., Chandarlapaty, Sarat, Rosen, Neal
Publicado no Cancer Cell (2014)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

Por Rodrik-Outmezguine, Vanessa S., Okaniwa, Masanori, Yao, Zhan, Novotny, Chris J., McWhirter, Claire, Banaji, Arpitha, Won, Helen, Wong, Wai, Berger, Mike, de Stanchina, Elisa, Barratt, Derek G., Cosulich, Sabina, Klinowska, Teresa, Rosen, Neal, Shokat, Kevan M.
Publicado no Nature (2016)

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

Por Xu, Jianing, Pham, Can G., Albanese, Steven K., Dong, Yiyu, Oyama, Toshinao, Lee, Chung-Han, Rodrik-Outmezguine, Vanessa, Yao, Zhan, Han, Song, Chen, David, Parton, Daniel L., Chodera, John D., Rosen, Neal, Cheng, Emily H., Hsieh, James J.
Publicado no J Clin Invest (2016)

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Por Yao, Zhan, Yaeger, Rona, Rodrik-Outmezguine, Vanessa S., Tao, Anthony, Torres, Neilawattie M., Chang, Matthew T., Drosten, Matthias, Zhao, Huiyong, Cecchi, Fabiola, Hembrough, Todd, Michels, Judith, Baumert, Hervé, Miles, Linde, Campbell, Naomi M., de Stanchina, Elisa, Solit, David B., Barbacid, Mariano, Taylor, Barry S., Rosen, Neal
Publicado no Nature (2017)

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

Por Elkabets, Moshe, Vora, Sadhna, Juric, Dejan, Morse, Natasha, Mino-Kenudson, Mari, Muranen, Taru, Tao, Jessica, Campos, Ana Bosch, Rodon, Jordi, Ibrahim, Yasir H., Serra, Violeta, Rodrik-Outmezguine, Vanessa, Hazra, Saswati, Singh, Sharat, Kim, Phillip, Quadt, Cornelia, Liu, Manway, Huang, Alan, Rosen, Neal, Engelman, Jeffrey A., Scaltriti, Maurizio, Baselga, José
Publicado em 2013